[go: up one dir, main page]

GT200000183AA - BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS - Google Patents

BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS

Info

Publication number
GT200000183AA
GT200000183AA GT200000183AK GT200000183K GT200000183AA GT 200000183A A GT200000183A A GT 200000183AA GT 200000183A K GT200000183A K GT 200000183AK GT 200000183 K GT200000183 K GT 200000183K GT 200000183A A GT200000183A A GT 200000183AA
Authority
GT
Guatemala
Prior art keywords
amino acids
bicycle
pharmaceutical agents
disorders
compounds
Prior art date
Application number
GT200000183AK
Other languages
Spanish (es)
Inventor
Justin Stephen Bryans
David Clive Blakemore
Simon Osborne
Jean-Marie Receveur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200000183AA publication Critical patent/GT200000183AA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)

Abstract

LOS COMPUESTOS DE LA PRESENTE INVENCION SON AMINOACIDOS BICICLICOS UTILES EN EL TRATAMIENTO DE LA EPILEPSIA, LOS ATAQUES DE DESMAYO, HIPOQUINESIA, TRASTORNOS CRANEANOS, TRASTORNOS NEURODEGENERATIVOS, DEPRESION, ANSIEDAD, PANICO, DOLOR, ARTRITIS, TRASTORNOS NEUROPATOLOGICOS, Y TRASTORNOS DEL SUEÑO. LOS PROCESOS PARA LA PREPARACION DE LOS PRODUCTOS FINALES Y LOS INTERMEDIARIOS DE SINTESIS UTILES EN EL PROCESO ESTAN INCLUIDOS. TAMBIEN ESTAN INCLUIDAS LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN UNO O MAS DE LOS COMPUESTOS.The compounds of the present invention are amino acids bicyclic useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, and impaired sleep. THE PROCESSES FOR THE PREPARATION OF FINAL PRODUCTS AND USEFUL SYNTHESIS INTERMEDIARIES IN THE PROCESS ARE INCLUDED. ALSO THE PHARMACEUTICAL COMPOSITIONS CONTAINING ONE OR MORE OF THE COMPOUNDS ARE INCLUDED.

GT200000183AK 1999-10-20 2000-10-19 BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS GT200000183AA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20

Publications (1)

Publication Number Publication Date
GT200000183AA true GT200000183AA (en) 2005-06-17

Family

ID=22578159

Family Applications (2)

Application Number Title Priority Date Filing Date
GT200000183AK GT200000183AA (en) 1999-10-20 2000-10-19 BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS
GT200000183A GT200000183A (en) 1999-10-20 2000-10-19 BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS.

Family Applications After (1)

Application Number Title Priority Date Filing Date
GT200000183A GT200000183A (en) 1999-10-20 2000-10-19 BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS.

Country Status (50)

Country Link
US (2) US6689906B1 (en)
EP (2) EP1226110B1 (en)
JP (2) JP3632191B2 (en)
KR (2) KR100593349B1 (en)
CN (1) CN1165518C (en)
AP (2) AP2004003186A0 (en)
AR (2) AR026087A1 (en)
AT (2) ATE293590T1 (en)
AU (2) AU778871B2 (en)
BG (2) BG106719A (en)
BR (1) BR0014972B1 (en)
CA (1) CA2386297C (en)
CO (1) CO5280060A1 (en)
CR (1) CR6620A (en)
CU (1) CU23112A3 (en)
CZ (1) CZ295960B6 (en)
DE (2) DE60019628T2 (en)
DO (1) DOP2000000083A (en)
DZ (1) DZ3197A1 (en)
EA (1) EA005206B1 (en)
EC (1) ECSP045393A (en)
EE (1) EE200200211A (en)
ES (2) ES2237464T3 (en)
GE (1) GEP20043297B (en)
GT (2) GT200000183AA (en)
HK (1) HK1049826B (en)
HN (1) HN2000000224A (en)
HR (2) HRP20040709A2 (en)
HU (1) HUP0203325A3 (en)
IL (3) IL149143A0 (en)
IS (2) IS6348A (en)
MA (1) MA26842A1 (en)
MX (1) MXPA02003229A (en)
MY (1) MY127678A (en)
NO (2) NO20021780L (en)
NZ (1) NZ517961A (en)
OA (1) OA12070A (en)
PA (1) PA8505201A1 (en)
PE (1) PE20010740A1 (en)
PL (1) PL354607A1 (en)
PT (1) PT1226110E (en)
SI (1) SI1226110T1 (en)
SK (1) SK5232002A3 (en)
SV (1) SV2001000188A (en)
TR (2) TR200500221T2 (en)
TW (2) TWI225855B (en)
UA (1) UA72931C2 (en)
WO (1) WO2001028978A1 (en)
YU (2) YU29302A (en)
ZA (1) ZA200202543B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
AU6473601A (en) * 2000-06-26 2002-01-08 Warner Lambert Co Gabapentin analogues for sleep disorders
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
WO2002085839A1 (en) * 2001-04-19 2002-10-31 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE540678T1 (en) * 2001-06-11 2012-01-15 Xenoport Inc GABA ANALOG PRODRUGS, COMPOSITIONS AND USES THEREOF
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
NZ532624A (en) * 2002-01-31 2007-05-31 Warner Lambert Co Alpha2delta ligands to treat tinnitus
WO2003070237A1 (en) * 2002-02-22 2003-08-28 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
EP1515709A2 (en) * 2002-06-27 2005-03-23 Warner-Lambert Company LLC Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
WO2004016260A1 (en) * 2002-08-15 2004-02-26 Pfizer Limited Therapeutic use of fused bicyclic or tricyclic amino acids
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
NZ540591A (en) 2002-12-13 2008-03-28 Warner Lambert Co Pregabalin derivatives for the treatment of fibromyalgia and other disorders
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PT1572173E (en) 2002-12-13 2010-05-10 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2537402C (en) 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AR061728A1 (en) * 2006-06-30 2008-09-17 Pfizer Prod Inc COMPOSITION FOR TREATMENT USING SELECTIVE COMPOUNDS ALFA-2-DELTA-1
CN101600458A (en) 2006-12-22 2009-12-09 瑞蔻达蒂爱尔兰有限公司 Combination therapy of lower urinary tract diseases with α2δ ligands and NSAIDs
CN101878193B (en) 2007-09-28 2014-07-09 第一三共株式会社 Bicyclic γ-amino acid derivatives
ES2635354T3 (en) 2009-03-26 2017-10-03 Daiichi Sankyo Company, Limited Production procedure of a bicyclic gamma-amino acid derivative
KR101816336B1 (en) 2011-06-08 2018-01-08 다이이찌 산쿄 가부시키가이샤 Method for producing bicyclic compound via iminium salt
JP5980780B2 (en) 2011-06-08 2016-08-31 第一三共株式会社 Method for producing bicyclic compound by Claisen rearrangement reaction
CA2859003C (en) 2011-12-15 2016-11-01 Daiichi Sankyo Company, Limited Optical resolution method for bicyclic compound using asymmetric catalyst
BR112014025158B1 (en) 2012-04-10 2021-09-21 Daiichi Sankyo Company, Limited METHOD FOR PRODUCING A COMPOUND
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (en) 2013-07-08 2018-09-11 第一三共股份有限公司 OPTICALLY ACTIVE BICYCLIC γ-AMINO ACID AND PREPARATION METHOD FOR THE SAME
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN113045410A (en) * 2021-03-29 2021-06-29 华东理工大学 Bicyclic norditerpenoid compound and synthetic gene and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) * 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (en) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds
ES2260850T3 (en) 1997-10-27 2006-11-01 Warner-Lambert Company Llc CYCLINE AMINOACIDS AND ITS DERIVATIVES USED AS PHARMACEUTICAL AGENTS.

Also Published As

Publication number Publication date
DE60034157T2 (en) 2007-12-13
ES2282785T3 (en) 2007-10-16
IS7497A (en) 2004-10-08
ES2237464T3 (en) 2005-08-01
US6835751B2 (en) 2004-12-28
NO20021780D0 (en) 2002-04-16
KR100593349B1 (en) 2006-06-26
GEP20043297B (en) 2004-01-12
GT200000183A (en) 2000-10-19
BR0014972B1 (en) 2011-09-06
ATE358116T1 (en) 2007-04-15
HRP20040709A2 (en) 2004-12-31
DE60034157D1 (en) 2007-05-10
AU1092001A (en) 2001-04-30
EP1506955B1 (en) 2007-03-28
JP3632191B2 (en) 2005-03-23
BG108860A (en) 2006-03-31
PT1226110E (en) 2005-07-29
YU73004A (en) 2005-11-28
EE200200211A (en) 2003-06-16
TWI225855B (en) 2005-01-01
NO20021780L (en) 2002-04-16
MXPA02003229A (en) 2002-09-30
DOP2000000083A (en) 2002-03-30
SK5232002A3 (en) 2003-07-01
TR200500221T2 (en) 2005-03-21
IL149143A (en) 2007-02-11
JP3744928B2 (en) 2006-02-15
HN2000000224A (en) 2001-04-11
KR100566462B1 (en) 2006-03-31
AU778871B2 (en) 2004-12-23
BG106719A (en) 2003-02-28
ECSP045393A (en) 2004-10-23
DE60019628T2 (en) 2006-01-19
HK1049826B (en) 2005-02-25
YU29302A (en) 2005-06-10
AP2002002517A0 (en) 2002-06-30
PL354607A1 (en) 2004-01-26
MA26842A1 (en) 2004-12-20
HK1049826A1 (en) 2003-05-30
TW200505824A (en) 2005-02-16
HRP20020428B1 (en) 2006-02-28
HRP20020428A2 (en) 2005-02-28
NO20043663L (en) 2002-04-16
MY127678A (en) 2006-12-29
OA12070A (en) 2003-11-10
AP2004003186A0 (en) 2004-12-31
PE20010740A1 (en) 2001-07-27
CZ295960B6 (en) 2005-12-14
PA8505201A1 (en) 2002-08-29
AR026087A1 (en) 2002-12-26
SV2001000188A (en) 2001-09-07
IL149143A0 (en) 2002-11-10
CO5280060A1 (en) 2003-05-30
CN1165518C (en) 2004-09-08
CA2386297C (en) 2010-02-09
HUP0203325A2 (en) 2003-02-28
DZ3197A1 (en) 2001-04-26
EA200200293A1 (en) 2002-10-31
US20040152779A1 (en) 2004-08-05
EA005206B1 (en) 2004-12-30
AR045456A2 (en) 2005-10-26
TR200201094T2 (en) 2002-09-23
CU23112A3 (en) 2006-02-27
CN1382118A (en) 2002-11-27
US6689906B1 (en) 2004-02-10
KR20020040900A (en) 2002-05-30
JP2005036009A (en) 2005-02-10
KR20060013701A (en) 2006-02-13
EP1226110A1 (en) 2002-07-31
CR6620A (en) 2004-02-02
IS6348A (en) 2002-04-17
EP1226110B1 (en) 2005-04-20
ZA200202543B (en) 2003-09-23
DE60019628D1 (en) 2005-05-25
AU2005201268A1 (en) 2005-04-21
UA72931C2 (en) 2005-05-16
WO2001028978A1 (en) 2001-04-26
NZ517961A (en) 2002-12-20
CA2386297A1 (en) 2001-04-26
BR0014972A (en) 2002-07-16
CZ20021310A3 (en) 2003-05-14
EP1506955A1 (en) 2005-02-16
SI1226110T1 (en) 2005-08-31
JP2003512348A (en) 2003-04-02
HUP0203325A3 (en) 2003-12-29
IL164060A0 (en) 2005-12-18
ATE293590T1 (en) 2005-05-15

Similar Documents

Publication Publication Date Title
GT200000183AA (en) BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS
PA8543501A1 (en) CONDENSED BICYCLIC OR TRICYCLIC AMINO ACIDS
ES2176668T3 (en) NEW CYCLING AMINO ACIDS AS PHARMACEUTICAL AGENTS.
BR9813656A (en) Amines as pharmaceutical agents
BR9712651A (en) gamma-aminobutyric acids substituted with pharmaceutical agents.
CR7785A (en) TIAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
CR8380A (en) METHODS FOR PREPARING AND USING NEW DEVELOPMENTS OF MOTHER CELLS AND THEIR ASSEMBLIES
CL2011002206A1 (en) Compounds derived from substituted benzofuran, modulators of the igf1 signaling agent or activator of protein kinase b; pharmaceutical composition that includes them; Useful in the treatment of diseases of the CNS, such as Alzheimer's, among others.
PA8629801A1 (en) ESTEREOSELECTIVE BIOCONVERSION OF ALIFATIC DINITRILS IN CYANOCARBOXYL ACIDS
ECSP034804A (en) CONDENSED BICYCLIC OR TRICYCLIC AMINO ACIDS
PA8529701A1 (en) RETINOID COMPOUNDS
CR10062A (en) COMPOSITIONS AND METHODS OF TREATMENT FOR DISORDERS OF THE CENTRAL NERVOUS SYSTEM
UY28484A1 (en) COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
CR7802A (en) PROLINA DERIVATIVES PRESENTING AFFINITY FOR THE ALFA-2-DELTA SUBUNITY OF THE CALCIUM CHANNEL
ES2185591T3 (en) AMINO HEREROCICLES USEFUL AS PHARMACEUTICAL AGENTS.
ECSP003707A (en) DIAZEPANES
BR0306855A (en) Method for the treatment of cognitive disorders
GT200400231A (en) SULFONILTETRAHIDRO-3H-BENZO (E) INDOL-8-AMINA COMPOUNDS AS LIGANDS OF 5-HYDROXYTHYRIPTAMINE-6.
GT200100197A (en) DERIVATIVES OF TRIPTAMINE AND ANALOG COMPOUNDS, AND PHARMACEUTICAL FORMULATIONS CONTAINING IT.
PA8608601A1 (en) OXAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
DK1628663T3 (en) Process for the preparation of medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
UY27262A1 (en) CONDENSED BICYCLIC OR TRICYCLIC AMINO ACIDS
BRPI0509881A (en) therapeutic combination for treatment of alzheimer's disease
ES2140544T3 (en) USE OF EFAROXAN AND ITS DERIVATIVES FOR THE MANUFACTURE OF MEDICINES INTENDED FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES.
BRPI0408743A (en) formulations comprising tolterodine and cocoa powder and their use